UroGen Pharma Ltd.

UroGen Pharma has achieved a new 52-week high, reflecting a significant increase from its previous low and showcasing a strong one-year performance compared to the S&P 500. With a market capitalization of USD 836 million, the company exhibits impressive financial metrics despite currently being loss-making.

UroGen Pharma has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of USD 836 million, the company has shown strong financial metrics despite being loss-making and not offering dividends, highlighting the volatility in the biotechnology sector.

UroGen Pharma has achieved a new 52-week high, reflecting a substantial increase in its stock performance over the past year. With a market capitalization of USD 836 million, the company has demonstrated strong profitability metrics despite currently being loss-making, marking a significant moment in the pharmaceuticals sector.

UroGen Pharma has achieved a new 52-week high, reflecting a substantial increase in its stock value over the past year. With a market capitalization of USD 836 million, the company shows strong profitability metrics despite being loss-making. Its low debt level may enhance stability in the competitive biotechnology sector.

UroGen Pharma has achieved a new 52-week high, reflecting significant growth from its previous low. The company has outperformed the S&P 500 over the past year, with a market capitalization of USD 836 million. Despite losses, it shows strong return on equity and a unique financial structure.

UroGen Pharma has achieved a new 52-week high, reflecting a remarkable performance with a substantial increase over the past year. The company, with a market capitalization of USD 836 million, demonstrates strong financial metrics, including a high return on equity and a conservative debt-to-equity ratio.

UroGen Pharma has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. The company has seen a remarkable performance increase over the past year, with a market capitalization of USD 836 million and a high return on equity, despite currently being loss-making.

UroGen Pharma's shares rose significantly today, contrasting with a slight decline in the S&P 500. Over the past year, the stock has more than doubled, but year-to-date performance shows a decline. Financially, the company faces challenges, including a negative book value and concerns about debt servicing.

UroGen Pharma achieved a new 52-week high of USD 23.89 on November 7, 2025, marking an 81.99% increase over the past year. With a market capitalization of USD 991 million, the company has a notable return on equity of 165.96%, despite being currently loss-making.

UroGen Pharma has seen notable stock activity, with significant gains over various time frames, including a 121.03% increase year-to-date. Despite challenges such as a negative book value and slow long-term growth, the company boasts a high return on equity of 165.96%.

UroGen Pharma has achieved a new 52-week high of USD 23.64, significantly up from its low of USD 3.42, reflecting an impressive one-year performance. With a market cap of USD 991 million, the company shows strong financial metrics but remains loss-making, indicating evolving market dynamics in the Pharmaceuticals and Biotechnology sector.

UroGen Pharma's stock has shown strong performance, gaining 9.46% on October 24, 2025, and achieving a 56.78% return over the past year. Despite challenges such as a negative book value and modest long-term growth, the company's market capitalization is currently USD 991 million.

UroGen Pharma's stock surged significantly on September 30, 2025, reaching an intraday high and showcasing strong performance in the pharmaceuticals sector. Over the past year, the company has outperformed the S&P 500, but it faces challenges such as a negative book value and scrutiny over its debt servicing capabilities.

UroGen Pharma Ltd. has recently revised its evaluation amid changing market conditions. The stock, priced at $17.99, has shown resilience with a 32.87% return over the past year, outperforming the S&P 500. Despite challenges in longer-term performance, the company continues to navigate the competitive biotechnology landscape.